RESISTANCE TO ANTIPLATELET AGENTS IN PATIENTS BEFORE ELECTIVE CORONARY STENTING
- Authors: Sulimov V.1, Moroz E.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 23, No 4 (2012)
- Pages: 8-10
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115411
- ID: 115411
Cite item
Open Access
Access granted
Abstract
Coronary angioplasty that assumes the use of double antiaggregant (aspirin and clopidogrel) therapy holds the lead in the treatment of coronary heart disease. The major cause of stent thrombosis is resistance to these agents. The prevalence of resistance to aspirin and clopidogrel has been studied; its clinical risk factors have been identified.
Keywords
Full Text
About the authors
V. Sulimov
I.M. Sechenov First Moscow State Medical University
Email: moros@list.ru
Professor MD
E. Moroz
I.M. Sechenov First Moscow State Medical University
Email: moros@list.ru
References
- Методики клинических исследований: справочное пособие / под ред. В. В. Меньшикова. - М., 2008. - С. 156-157.
- Snoep J. Clopidogrel nonresponsiveness in patient undergoing percutaneous intervention with stenting: a systematic review and metaanalysis // Am. Heart. J. - 2007; 154: 221-231.
- Lee P., Chen W., Ng W. et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease // Am. J. Med. - 2005; 118: 723-727.
- Gurbel P., Bliden K., Hayes K. et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting // J. Am. Coll. Cardioll. - 2005; 45: 1392-1396.
- Gori A., Marcucci R., Migliorini A. et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents // J. Am. Coll. Cardiol. - 2008; 52 (9): 734-739.
- Sibbing D., Braun S., Morath T. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis // J. Am. Coll. Cardiol. - 2009; 53 (10): 849-856.
- Soffer D. // Catheter Cardiovasc Interv. - 2003; 59: 21.
- Ferguson A., Dokainish H., Lakkis N. Aspirin and clopidogrel response variability: review of the published literature // Tex. Heart. Inst. J. - 2008; 35 (3): 313-320.
- Bhatt D., Cryer B., Contant C. et. al. on Behalf of the COGENT Investigators. The COGENT Trial. Slide set. http: // www.clinicaltrialresults.org
- Hulot J. Cytochrome P4502 C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects // Blood. - 2006; 108: 2244-2247.
- Mega J. CYP2 С19*2 Genetic Variants and Clinical Outcomes With Clopidogrel: Meta-Analysis // Circulation. - 2009; 120: 598-599.
Supplementary files
